Belite Bio Inc ADR (BLTE) Stock Price, Quote & News

Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 246 6240

Website: www.belitebio.com

Address:

12750 High Bluff Drive, Suite 475, San Diego, United States

waterlock Jun. 25 at 1:59 AM

$BLTE bad news for BLTE https://www.fiercebiotech.com/biotech/sanofi-backed-splicebio-secures-135m-series-b-eye-disease-gene-therapy-trials

1 · Reply

swingingtech Jun. 6 at 9:37 PM

$BLTE https://wallstreetwaves.com/blte-experiences-significant-drop-below-essential-moving-average/

0 · Reply

justiceforb_85 Jun. 6 at 7:50 PM

$BLTE adding on this dip.

0 · Reply

justiceforb_85 May. 22 at 3:44 AM

$BLTE tinlarebant promising in Stargardt disease. However, appears P3 trial is in Japanese patients which will raise a significant concern with FDA. Are there any studies being conducted in US patients?

1 · Reply

MaverikIT May. 21 at 2:36 PM

@IsabellaDC $GPUS $WRD $BLTE

0 · Reply

SilverEagle May. 21 at 1:36 PM

$BLTE watching 👀 👀

0 · Reply

waterlock May. 21 at 10:52 AM

$BLTE ？？ BTD now? That sounds weird. Usually at much earlier time. At Phase 3?

0 · Reply

Thestocktraderhubzee May. 21 at 9:56 AM

WATCHLIST MAY 21 2025 $BLTE Belite Bio Secures FDA Breakthrough Therapy Designation For Tinlarebant In Stargardt Disease Following Phase 3 Interim Data $JNJ Reported Earlier, J&J's DARZALEX FASPRO Wins US FDA Oncologic Drugs Advisory Committee Backing For Early Intervention In HR-SMM, Potentially Preventing Disease Progression $PLTR Palantir Partners With SAP To Fuse Ontology, Foundry And Enterprise Data: CEO Alex Karp Calls It 'Extremely Valuable' $WRD WeRide Reveals Plan To Boost Commercial Robotaxi Services To 15 Additional Cities Globally $HD Home Depot Accelerates Supply Chain Diversification, Shifts Sourcing Away From Single Countries: Management Sees 'Limited Impact' From Tariffs

0 · Reply

SilverEagle May. 15 at 4:38 PM

$BLTE > 70 + volume may be special.

0 · Reply

JarvisFlow May. 15 at 3:24 PM

Cantor Fitzgerald has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Overweight.

0 · Reply

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

May 15, 2025, 11:53 AM EDT - 6 weeks ago

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

May 15, 2025, 4:59 AM EDT - 6 weeks ago

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:00 PM EDT - 6 weeks ago

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:35 AM EDT - 7 weeks ago

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

May 12, 2025, 8:00 AM EDT - 7 weeks ago

Belite Bio to Participate in Four Upcoming Investor Conferences

Mar 17, 2025, 6:40 PM EDT - 3 months ago

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:00 AM EDT - 3 months ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 17, 2025, 6:00 AM EDT - 3 months ago

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 3:00 AM EDT - 3 months ago

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 10:35 PM EST - 5 months ago

Belite Bio Announces Registered Direct Offering of $15 Million

Nov 27, 2024, 3:00 AM EST - 7 months ago

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Nov 12, 2024, 8:28 PM EST - 8 months ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 8:00 AM EST - 8 months ago

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Nov 3, 2024, 4:00 PM EST - 8 months ago

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Sep 1, 2024, 8:00 AM EDT - 10 months ago

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Aug 12, 2024, 10:35 PM EDT - 11 months ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 4:30 PM EDT - 11 months ago

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 8, 2024, 8:00 AM EDT - 11 months ago

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 5, 2024, 7:10 PM EDT - 11 months ago

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Jun 12, 2024, 2:55 AM EDT - 1 year ago

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

May 14, 2024, 8:11 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

May 13, 2024, 9:50 PM EDT - 1 year ago

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

May 6, 2024, 8:15 AM EDT - 1 year ago

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

May 6, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

May 1, 2024, 4:15 PM EDT - 1 year ago

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 25, 2024, 7:15 PM EDT - 1 year ago

Belite Bio Announces $25 Million Registered Direct Offering

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Mar 12, 2024, 7:53 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 10:28 PM EDT - 1 year ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 11, 2024, 9:27 PM EDT - 1 year ago

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 4, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Nov 30, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the BTIG Ophthalmology Day

Nov 14, 2023, 11:30 PM EST - 1 year ago

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 8:15 PM EST - 1 year ago

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 7, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 1 year ago

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Aug 22, 2023, 3:51 PM EDT - 2 years ago

Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?

Aug 13, 2023, 9:45 AM EDT - 2 years ago

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 10:17 PM EDT - 2 years ago

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 4, 2023, 8:00 AM EDT - 2 years ago

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Jul 27, 2023, 5:00 PM EDT - 2 years ago

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Jul 24, 2023, 6:04 AM EDT - 2 years ago

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

waterlock Jun. 25 at 1:59 AM

$BLTE bad news for BLTE https://www.fiercebiotech.com/biotech/sanofi-backed-splicebio-secures-135m-series-b-eye-disease-gene-therapy-trials

1 · Reply

swingingtech Jun. 6 at 9:37 PM

$BLTE https://wallstreetwaves.com/blte-experiences-significant-drop-below-essential-moving-average/

0 · Reply

justiceforb_85 Jun. 6 at 7:50 PM

$BLTE adding on this dip.

0 · Reply

justiceforb_85 May. 22 at 3:44 AM

1 · Reply

MaverikIT May. 21 at 2:36 PM

@IsabellaDC $GPUS $WRD $BLTE

0 · Reply

SilverEagle May. 21 at 1:36 PM

$BLTE watching 👀 👀

0 · Reply

waterlock May. 21 at 10:52 AM

$BLTE ？？ BTD now? That sounds weird. Usually at much earlier time. At Phase 3?

0 · Reply

Thestocktraderhubzee May. 21 at 9:56 AM

0 · Reply

SilverEagle May. 15 at 4:38 PM

$BLTE > 70 + volume may be special.

0 · Reply

JarvisFlow May. 15 at 3:24 PM

Cantor Fitzgerald has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Overweight.

0 · Reply

Doozio May. 15 at 3:19 PM

$BLTE and $ALNY both appear ready TTWO $EXEL INTA 🐒🍌🧠⏰♾️

0 · Reply

JarvisFlow May. 15 at 11:30 AM

HC Wainwright & Co. updates rating for Belite Bio ( $BLTE ) to Buy, target set at 100.

0 · Reply

DonCorleone77 May. 14 at 10:04 AM

$BLTE Belite Bio reports Q1 EPS (27c), consensus (37c) "We continue to advance the clinical development of Tinlarebant, reaching a major milestone with the favorable interim analysis of our Phase 3 DRAGON trial earlier this year," said Dr. Tom Lin, Chairman and CEO of Belite Bio. "We are excited by the encouraging feedback from the DSMB on the safety and efficacy outcomes in DRAGON as we work toward trial completion by the end of 2025. We are focused on maintaining strong execution across our late-stage clinical programs as we aim to deliver new treatment options for people living with degenerative retinal diseases, where there is significant unmet need."

0 · Reply

Armonica423 May. 6 at 2:59 PM

$BLTE CYDY

0 · Reply

Armonica423 May. 6 at 12:34 PM

$BLTE CYDY

0 · Reply

Doozio May. 5 at 1:19 PM

$BLTE went 3wt again during 🐑⏰♾️ NOW Roger got da huckleberries INTA 🐒🍌🧠⏰♾️

0 · Reply

PenkeTrading Apr. 23 at 12:53 PM

I found you a Bullish Engulfing Candle Pattern on the daily chart of Belite Bio Inc ADR. $BLTE #BullishEngulfingCandle #NASDAQ

0 · Reply

justiceforb_85 Apr. 16 at 4:50 AM

$BLTE data for tinlarebant likely to be presented in Q1'26. Is the stock priced in for perfection, though?

0 · Reply

trader_n Apr. 10 at 5:23 PM

$INTA $MMYT $BLTE $IWM

0 · Reply

TrendEdgeLogan Apr. 10 at 5:01 PM

Finding it tempting to put buys in a few favs $INTA $MMYT $BLTE and see if can get a better weekly close this time, unlike last week; but having a hard time finding the conviction Feel as though i'm thinking clearly, but the meatball is not there. I believe that when you are presented with a high conviction setup, it should be plain as day. Money sitting in the corner, just walk over and pick it up. I am going to have to continue to sit tight and wait for more information. I do know that ... 1) My Trend Edge indicators are flashing that we are in a bear/difficult market. 2) We are still in the 'falling knife' portion of this correction 3) While I do have a watchlist of fav names, they are all in no man's land for the most part. 4) I have never traded in an environment where the 200-week SMA (40-month SMA) in $IWM is declining as it is now

3 · Reply

Doozio Mar. 30 at 4:41 PM

$BLTE 3wt and a 🎾 if 🐑 amania passes. Acts da 🧠

1 · Reply

JarvisFlow Mar. 26 at 2:23 PM

Benchmark has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Buy with a target price of 80.

0 · Reply

Market Cap	1.88B
Revenue (ttm)	0.00
Net Income (ttm)	-36.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	46,718
Avg Vol	31,432
Day's Range	N/A - N/A
Shares Out	31.84M
Stochastic %K	12%
Beta	-1.44
Analysts	Strong Sell
Price Target	$85.00